After reporting first-quarter results, shares of Sarepta Therapeutics (NASDAQ: SRPT), a commercial-stage biotech focused on rare diseases, jumped 14% as of 3:40 p.m. EDT Friday.Here's a review of the key numbers from the first quarter:Looking beyond the financial statements, Sarepta also recently signed an exclusive partnership deal with Myonexus Therapeutics. The move expands the company's pipeline from 16 programs to 21.Continue reading